Work Here?
Overview
Conception.bio develops fertility treatments by turning a person’s blood cells into mature egg cells using induced pluripotent stem cell (iPSC) technology. Blood is collected, reprogrammed into iPSCs, and guided to become viable eggs that can be used for reproduction, with optional genetic screening of embryos. It differentiates itself by producing patient-derived eggs from blood and selling directly to consumers, bypassing traditional clinic pathways. The goal is to broaden access to fertility options by enabling later-life parenting and embryo genetic screening through a patient-derived egg platform with a direct-to-consumer model.
About Conception
Industries
Biotechnology
Healthcare
Company Size
51-200
Company Stage
Early VC
Total Funding
$20M
Headquarters
Berkeley, California
Founded
2017
Get referred to Conception
See people who can refer or advise you
Simplify's Take
What believers are saying
- July 2026 breakthrough validates Conception's platform and attracts fertility investors.
- PitchBook listed $38M raised by 2025; company now claims >$60M.
- Fertility demand stays huge: age-related infertility and cancer survivors need better options.
What critics are saying
- July 2026: Conception still lacks full antral follicles and clinical-trial readiness.
- Safety studies and animal testing remain mandatory, delaying human use for years.
- Ethical backlash or FDA restraint on IVG could freeze commercialization entirely.
What makes Conception unique
- July 2026: Conception generated first early human egg cells from stem cells.
- Conception uses blood-draw iPSCs and miniature ovaries, not donor eggs.
- Berkeley team spans 11-50 employees and claims >$60M backing.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$20M
Above
Industry Average
Funded Over
1 Rounds
Benefits
Health Insurance
Company Equity
Flexible Work Hours
Growth & Insights and Company News
6 month growth
↓ -1%1 year growth
↑ 1%2 year growth
↓ -3%iPS 細胞については、山中伸弥氏（現在、京都大学 iPS 細胞研究所長・教授）が2012年にノーベル医学・生理学賞を受賞したことを契機に、我々も日常的に耳にするようになった。iPS 細胞の日本語での正式名称は人工多能性幹細胞、つまり、そこからヒト（ヒトに限らず、あらゆる生物に適用可能だが）のあらゆる身体部位の細胞に変化させられる細胞のことだ。事故や病気などで損傷や摘出した臓器や組織の再生医療の分野で注目を集めている。. 倫理的課題はあるものの、この iPS 細胞から卵子（卵細胞）を作製することができれば、妊娠や生殖にまつわる多くの問題を解決することができるだろう。まず、卵子の老化・閉経・排卵障害といった問題を回避できるため、女性は何歳でも妊娠できるようになる。子宮に問題があっても、受精卵を預かってくれる代理母を見つけられれば、生まれてくる子供は自分の遺伝子を受け継ぐことになる。男性からも卵子を作製できるから、男性同士のカップルも子供の biological parents になれるのだ。
This is going to be a massive moral and ethical debate in the coming years…
Conception is Hiring for 5 Jobs on Simplify!
Find jobs on Simplify and start your career today
About Conception
Industries
Biotechnology
Healthcare
Company Size
51-200
Company Stage
Early VC
Total Funding
$20M
Headquarters
Berkeley, California
Founded
2017
Conception is Hiring for 5 Jobs on Simplify!
Find jobs on Simplify and start your career today